All News
Did Your Specialty Choose You?
Why did I end up a rheumatologist? Circumstance, personality types, horoscopes or what? A current study in BMJ sheds light on why.
Read Article
ICYMI: Dr Eric Ruderman presents on paraneoplastic syndromes. Many autoantibodies have been possibly implicated. #RWCS2022 https://t.co/R2mfpJLsLo https://t.co/twZLk0v3b6 https://t.co/ex1q8JQDe5
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Challenges in Lupus:
-Mortality greatest in 1st yr
-Dx Delays 6.4 yrs
-Long-term complications increased 50 fold
-Steroids worsen long-term outcomes
-Health care costs increased 3 to 5 years prior to Dx
-Mean delay in drug starts after Dx =177 days https://t.co/ZMHTXBn4vm https://t.co/SX0fSxHoES
Links:
Dr. John Cush RheumNow ( View Tweet)
The new updated 2022 ACIP immunization schedule for adults has been published. https://t.co/EXCjnjLrlw https://t.co/hewbEmI60t
Links:
Dr. John Cush RheumNow ( View Tweet)
Doximity ranked 15 specialties w/ high telehealth adoption rates
1 Endocrinology
2 GI
3. Rheumatology
4 GU
5 Nephrology
6 Cardiology
7 ENT
8 Neuro
9 Allergy
10 Heme/Onc
11Family medicine
12 Dermatology
13 Geriatrics
14 Pulm
15 Psych https://t.co/d7xm1ovk15
Links:
Dr. John Cush RheumNow ( View Tweet)
Future considerations and treatment directions in systemic sclerosis per Dr Steen. #RWCS2022 @RWCSmtg https://t.co/FaJaJ9G5lU
Dr. John Cush RheumNow ( View Tweet)
Stem cell transplant has clear benefits on survival and skin thickening. #RWCS2022 @RWCSmtg https://t.co/UnGxLQzy0Q
Dr. John Cush RheumNow ( View Tweet)
GAVE - gastric antral vascular ectasia. AKA "watermelon stomach". Is pretty rare https://t.co/DcU0J2TNrN
Dr. John Cush RheumNow ( View Tweet)
Dr Steen's recipe to freaking with digital ulcers.#RWCS2022 @RWCSmtg https://t.co/VmDag701JC
Dr. John Cush RheumNow ( View Tweet)
Subsets of scleroderma defined by autoantibodies. #RWCS2022 @RWCSmtg https://t.co/ywe0yrHmWd
Dr. John Cush RheumNow ( View Tweet)
Many failed clinical trials in Scleroderma in the past. #RWCS2022 @RWCSmtg https://t.co/2PBfHAnqWu
Dr. John Cush RheumNow ( View Tweet)
Predicting Treatment Response in Inflammatory Muscle Disorders
Rheums looking for clues to whether their patients w/certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study in Arthritis Care & Research.
https://t.co/kXFIEMTbkb https://t.co/UbO7nSsdAY
Links:
Dr. John Cush RheumNow ( View Tweet)
Significant mortality risk with scleroderma renal crisis. #RWCS2022 @RWCSmtg https://t.co/vIm0xDEjB3
Dr. John Cush RheumNow ( View Tweet)
Scleroderma ANA associations thru the ages. Dr. Virginia Steen
@RWCSmtg #RWCS2022 https://t.co/U64gpnCgS8
Dr. John Cush RheumNow ( View Tweet)
Would combination biologics work? Maybe according to this collection of antecdotal use. #RWCS2022 @RWCSmtg https://t.co/VJdINyqLQt
Dr. John Cush RheumNow ( View Tweet)
NOR-DRUM study shows that TDM, therapeutic drug monitoring, is beneficial. Study of RA, PSA, AS, Crohn's, UC Rheums don't do this, should they? #RWCS2022 @RWCSmtg https://t.co/Dc6mgr5jrL
Dr. John Cush RheumNow ( View Tweet)
IMPACT2 shows what we see in most PSA trials- little x-ray progression. #RWCS2022 @RWCSmtg https://t.co/uYXHB0s8g0
Dr. John Cush RheumNow ( View Tweet)
Dr Artie Kavanaugh presents comparison of targeted therapies in different inflammatory disorders. #RWCS2022 @RWCSmtg https://t.co/cX00RUOgAq
Dr. John Cush RheumNow ( View Tweet)
Fecal transplant (FMT) failed to help #PsA, small trial, unexpected result. #RWCS2022 @RWCSmtg https://t.co/zKq6FONuwk
Dr. John Cush RheumNow ( View Tweet)
Proposed new pathways involving the inhibition or deletion of kindlin-2, Stat3 and Runx2 in articular chondrocytes that promotes cartilage degradation and osteoarthritis -- potential new therapeutic target for OA https://t.co/EFgGctoYJY
Dr. John Cush RheumNow ( View Tweet)
